Diagnostic and Risk Criteria for Complement Defects in Thrombotic Microangiopathy and Related Conditions Including Severe Hypertension: The COMPETE Study

What this Trial Is About

Thrombotic microangiopathy (TMA) is a serious condition affecting the kidneys and brain, often linked to a problem in the complement system called primary atypical hemolytic uremic syndrome (HUS). This condition can arise from various clinical situations, and researchers believe that a new test called the "HMEC" test can better classify TMA types. This may help guide treatment and predict outcomes, moving toward more personalized care for patients with TMA. The study observes patients with different forms of TMA, including those with primary atypical HUS and secondary atypical HUS linked to other conditions like severe hypertension, pregnancy, or autoimmune diseases. Participants will be monitored using the HMEC test along with other routine measures to understand complement involvement. The study focuses on how complement dysregulation influences disease progression and response, without introducing new treatments. Participants will be followed for up to one year, with monthly blood tests and kidney function assessments to track disease course and complement activity. Researchers will measure the prevalence of complement-mediated TMA, kidney outcomes, and the accuracy of the HMEC test. The study aims to improve diagnosis and risk assessment for patients with TMA while ensuring safety through careful monitoring and data collection throughout the study period.

Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium